Kemin Health, L.C., creator of FloraGLO lutein, and DSM Nutritional Products recently presented new research demonstrating the bioavailability of FloraGLO Lutein with Actilease technology.

Lutein bioavailability, or the delivery of the ingredient to the beneficial sites of action, including the macula where lutein is quantified as macular pigment optical density (MPOD) is essential for eye health. Research supports that MPOD has the potential to become a commonly tested biomarker in the assessment of visual function and the risk for eye disease. Awareness of MPOD and the technology used for its measurement are growing among eye care practitioners and consumers.

FloraGLO lutein beadlets utilize Actilease beadlet technology, a branded, patented technology from DSM that formulates FloraGLO lutein into micro-sized particles that are protected in a water-soluble shell. Published research shows that FloraGLO Lutein, with Actilease technology, is absorbed by the body into the bloodstream and, more importantly, deposited into the macula increasing MPOD. For further information: www.kemin.com; www.dsmnutritionalproducts.com